Do all metastatic breast cancer patients deserve genetic testing? September 13, 2019 -- National Comprehensive Cancer Network guidelines should be changed to advise genetic testing for all patients with metastatic breast cancer, according to a recent study in JAMA Oncology. Profiling is needed so that patients won't miss out on targeted clinical trials and drug therapies, the researchers explained. Discuss
Veracyte validates Afirma XA in thyroid cancer September 13, 2019 -- Veracyte published data in Frontiers in Endocrinology on September 11 supporting the utility of its Afirma Expression Atlas (XA) test for identifying gene alterations in patients suspected to have or diagnosed with thyroid cancer.
Blood test helps gauge lung cancer risk in heavy smokers September 11, 2019 -- Pairing a microRNA blood test with low-dose computed tomography scans helps assess risk for lung cancer and guide screening efforts, according to an Italian study of heavy smokers presented during a presidential symposium on September 9 at the World Conference on Lung Cancer in Barcelona, Spain. Discuss
Personal Genome Diagnostics touts liquid biopsy data September 10, 2019 -- Personal Genome Diagnostics reported positive study results for a 58-gene panel liquid biopsy test for assessing microsatellite instability and tumor mutational burden in an article published online September 10 in Clinical Cancer Research. Discuss
Many cancer patients don't understand genetic test results September 10, 2019 -- Many cancer patients who participate in biomarker-driven clinical trials don't understand the potential uses of genomic test results, according to results from a telephone survey presented on September 9 at the World Conference on Lung Cancer in Barcelona, Spain.
CAP offers guideline on molecular testing in brain cancer September 9, 2019 -- The College of American Pathologists (CAP) on September 9 released new draft recommendations on biomarkers for diffuse gliomas, the most common group of primary brain tumors. The move recognizes the growing importance of molecular testing in tumor classification. Discuss
Thermo Fisher seals companion test deal with Lilly September 9, 2019 -- Thermo Fisher Scientific has signed an agreement to develop its Oncomine Dx for use as a companion test with Lilly's LOXO-292 drug in non-small cell lung cancer and thyroid cancer.
Thermo Fisher flags data for tumor mutation test September 6, 2019 -- Thermo Fisher Scientific will showcase new research involving its Oncomine tumor mutation load assay and how it relates to cancer immunotherapy response on September 9 at the European Congress of Pathology in Nice, France.